Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

D1-D2 Dopamine Receptor Synergy Promotes Calcium Signaling via Multiple Mechanisms

Lani S. Chun, R. Benjamin Free, Trevor B. Doyle, Xi-Ping Huang, Michele L. Rankin and David R. Sibley
Molecular Pharmacology August 2013, 84 (2) 190-200; DOI: https://doi.org/10.1124/mol.113.085175
Lani S. Chun
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Benjamin Free
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevor B. Doyle
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi-Ping Huang
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele L. Rankin
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Sibley
Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 84 no. 2 190-200
DOI 
https://doi.org/10.1124/mol.113.085175
PubMed 
23680635

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received January 24, 2013
  • Accepted May 16, 2013
  • Published online July 16, 2013.

Article Versions

  • Earlier version (May 16, 2013 - 09:56).
  • You are viewing the most recent version of this article.
Copyright & Usage 
U.S. Government work not protected by U.S. copyright

Author Information

  1. Lani S. Chun,
  2. R. Benjamin Free,
  3. Trevor B. Doyle,
  4. Xi-Ping Huang,
  5. Michele L. Rankin, and
  6. David R. Sibley
  1. Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (L.S.C., R.B.F., T.B.D., M.L.R., D.R.S.); Cellular, Molecular, Developmental Biology & Biophysics Program, Johns Hopkins University, Baltimore, Maryland (L.S.C.); and National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (X.-P.H.)
  1. Address correspondence to:
    Dr. David R. Sibley, Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, 5625 Fishers Lane, Room 4S-04, Bethesda, MD 20892-9405. E-mail: sibleyd{at}helix.nih.gov
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2013 to May 2022

AbstractFullPdf
May 201321413144
Jun 2013117098
Jul 201348340150
Aug 20132842660
Sep 20131182650
Oct 2013622735
Nov 2013632138
Dec 2013591929
Jan 2014642833
Feb 201439139
Mar 2014352227
Apr 2014272015
May 2014262028
Jun 2014351718
Jul 2014232414
Aug 2014231616
Sep 2014222024
Oct 2014303222
Nov 2014282716
Dec 2014262517
Jan 2015422324
Feb 2015281817
Mar 2015171616
Apr 2015251812
May 2015261523
Jun 2015292116
Jul 2015381818
Aug 2015172223
Sep 201523144
Oct 201511710
Nov 2015222313
Dec 201521814
Jan 2016331326
Feb 201650627
Mar 201622933
Apr 2016591615
May 2016372515
Jun 2016171612
Jul 2016142014
Aug 2016231218
Sep 201612165
Oct 201612412
Nov 201612316
Dec 20163283
Jan 20171407
Feb 20175347
Mar 20175427
Apr 20175398
May 201784623
Jun 201738420
Jul 201772922
Aug 201742013
Sep 201763415
Oct 201723922
Nov 201713022
Dec 201722923
Jan 201812527
Feb 201842930
Mar 20183298
Apr 201843150
May 201822515
Jun 201822930
Jul 201813315
Aug 20182157
Sep 201832610
Oct 201895519
Nov 201813021
Dec 20181886
Jan 20192335
Feb 20193807
Mar 20191836
Apr 20192514
May 20192514
Jun 201924216
Jul 20191524
Aug 20192565
Sep 20193364
Oct 201920117
Nov 20192638
Dec 20192638
Jan 20201311
Feb 20202843
Mar 20201721
Apr 20201703
May 20201623
Jun 20201809
Jul 20202901
Aug 2020614
Sep 20201013
Oct 20202301
Nov 202042412
Dec 20204145
Jan 20211988
Feb 20212798
Mar 20212748
Apr 20214238
May 20214522
Jun 20213362
Jul 20212723
Aug 20212791
Sep 20211132
Oct 20213655
Nov 20213138
Dec 202122310
Jan 20223832
Feb 20221925
Mar 20221834
Apr 20222668
May 20221300

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 84 (2)
Molecular Pharmacology
Vol. 84, Issue 2
1 Aug 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
D1-D2 Dopamine Receptor Synergy Promotes Calcium Signaling via Multiple Mechanisms
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

D1-D2 Receptor Synergy and Ca2+ Signaling

Lani S. Chun, R. Benjamin Free, Trevor B. Doyle, Xi-Ping Huang, Michele L. Rankin and David R. Sibley
Molecular Pharmacology August 1, 2013, 84 (2) 190-200; DOI: https://doi.org/10.1124/mol.113.085175

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

D1-D2 Receptor Synergy and Ca2+ Signaling

Lani S. Chun, R. Benjamin Free, Trevor B. Doyle, Xi-Ping Huang, Michele L. Rankin and David R. Sibley
Molecular Pharmacology August 1, 2013, 84 (2) 190-200; DOI: https://doi.org/10.1124/mol.113.085175
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics